Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients : Final 5-Year Results From STARTMRK

dc.creatorRockstroh, Jürgen K.
dc.creatorDeJesus, Edwin
dc.creatorLennox, Jeffrey L.
dc.date2020-09-10T23:42:28Z
dc.date2023-05-11T17:04:29Z
dc.date2020-09-10T23:42:28Z
dc.date2023-05-11T17:04:29Z
dc.date2013-05
dc.date.accessioned2023-08-24T04:57:19Z
dc.date.available2023-08-24T04:57:19Z
dc.identifierhttps://journals.lww.com/jaids/Fulltext/2013/05010/Durable_Efficacy_and_Safety_of_Raltegravir_Versus.11.aspx
dc.identifier1525-4135 / 1944-7884 (Electrónico)
dc.identifierhttps://hdl.handle.net/20.500.12032/103481
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8407020
dc.formatPDF
dc.formatapplication/pdf
dc.languageInglés
dc.rightshttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceJournal of Acquired Immune Deficiency Syndromes; Vol. 63 Núm. 1 (2013)
dc.titleDurable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients : Final 5-Year Results From STARTMRK
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución